See more : Argo Blockchain plc (ARBKF) Income Statement Analysis – Financial Results
Complete financial analysis of BioVie Inc. (BIVI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioVie Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- IndusInd Bank Limited (INDUSINDBK.NS) Income Statement Analysis – Financial Results
- Nowigence, Inc. (NOWG) Income Statement Analysis – Financial Results
- Genkyotex SA (GKTX.PA) Income Statement Analysis – Financial Results
- Molecular Energies PLC (MEN.L) Income Statement Analysis – Financial Results
- Energy International Investments Holdings Limited (0353.HK) Income Statement Analysis – Financial Results
BioVie Inc. (BIVI)
About BioVie Inc.
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 229.38K | 266.84K | 237.42K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -229.38K | -266.84K | -237.42K | -229.38K | -229.38K | -229.38K | -229.38K | -229.38K | -51.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.10M | 33.30M | 17.26M | 133.19M | 1.15M | 1.01M | 370.85K | 466.35K | 37.90K | 4.20K | 49.42K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 1.77M | 857.88K | 343.09K | 229.18K | 272.97K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.85M | 11.55M | 9.77M | 4.64M | 1.31M | 1.26M | 1.77M | 857.88K | 343.09K | 229.18K | 272.97K | 70.06K |
| Other Expenses | 0.00 | 229.38M | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 212.71K | 247.08K | 0.00 |
| Operating Expenses | 31.95M | 45.08M | 27.25M | 138.05M | 2.69M | 2.50M | 2.37M | 1.55M | 432.03K | 233.38K | 322.39K | 70.06K |
| Cost & Expenses | 32.18M | 45.08M | 27.25M | 138.05M | 2.69M | 2.50M | 2.37M | 1.55M | 432.03K | 233.38K | 322.39K | 70.06K |
| Interest Income | 1.14M | 562.26K | 44.08K | 21.97K | 234.00 | 1.16K | 4.00 | 14.00 | 186.00 | 369.00 | 489.00 | 20.00 |
| Interest Expense | 2.89M | 4.30M | 2.16M | 559.46K | 4.77M | 273.00 | 40.96K | 0.00 | 81.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 229.38K | 266.84K | 237.42K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 369.00 | 489.00 | 70.06K |
| EBITDA | -31.95M | -45.69M | -23.68M | -137.80M | -2.46M | -2.27M | -2.14M | -1.32M | -380.81K | -233.01K | -321.90K | 20.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.18M | -45.08M | -27.25M | -138.05M | -2.69M | -2.50M | -2.37M | -1.55M | -432.03K | -233.38K | -322.39K | -70.06K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 59.05K | -5.18M | 1.17M | 7.80M | -13.98M | 52.29K | -40.96K | 222.94K | 105.00 | 369.00 | 489.00 | 20.00 |
| Income Before Tax | -32.12M | -50.26M | -26.08M | -130.25M | -16.68M | -2.44M | -2.41M | -1.33M | -431.92K | -233.01K | -321.90K | -70.04K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.30M | -3.29M | 559.46K | 4.77M | -51.40K | -1.00 | -222.93K | -105.00 | -369.00 | -489.00 | 20.00 |
| Net Income | -32.12M | -50.26M | -26.08M | -183.85M | -33.78M | -2.49M | -2.43M | -1.33M | -431.92K | -233.01K | -321.90K | -70.04K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.30 | -15.47 | -10.58 | -148.23 | -68.52 | -9.82 | -31.77 | -18.61 | -6.19 | -3.34 | -4.62 | 0.00 |
| EPS Diluted | -7.30 | -15.50 | -10.60 | -148.23 | -68.52 | -9.82 | -31.77 | -18.61 | -6.19 | -3.34 | -4.62 | 0.00 |
| Weighted Avg Shares Out | 4.52M | 3.24M | 2.46M | 1.24M | 492.00K | 253.00K | 76.00K | 71.00K | 69.00K | 69.00K | 69.00K | 32.98K |
| Weighted Avg Shares Out (Dil) | 4.52M | 3.25M | 2.47M | 1.24M | 492.95K | 253.96K | 76.61K | 71.51K | 69.76K | 69.77K | 69.67K | 32.98K |
BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients
Full Dataset from Phase 2a trial in Parkinson's Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worsened
BioVie secures $13.1M funding from US Department of Defense for Long COVID treatment
BioVie Inc (NASDAQ:BIVI), a clinical-stage company focused on innovative drug therapies, announced today the approval of a clinical trial award of up to $13.1 million from the U.S. Department of Defense (DOD) to evaluate Bezisterim (NE3107) for treating neurological symptoms...
BioVie secures $13.1M funding from US Department of Defense for Long COVID treatment
BioVie Inc (NASDAQ:BIVI), a clinical-stage company focused on innovative drug therapies, announced today the approval of a clinical trial award of up to $13.1 million from the U.S. Department of Defense (DOD) to evaluate Bezisterim (NE3107) for treating neurological symptoms...
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID
BioVie presents new data showing lead drug asset may promote healthier aging
BioVie Inc (NASDAQ:BIVI) announced that it has presented data showing its lead drug asset NE3107 may restore homeostasis via specific genes associated with dementia, metabolism and inflammation at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit held in Boston...
BioVie presents new data showing lead drug asset may promote healthier aging
BioVie Inc (NASDAQ:BIVI) announced that it has presented data showing its lead drug asset NE3107 may restore homeostasis via specific genes associated with dementia, metabolism and inflammation at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit held in Boston...
BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints
CARSON CITY, Nev., April 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease, today announced that...
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation
Additionally, the Company announced approval of the non-proprietary name “bezisterim” for NE3107 Additionally, the Company announced approval of the non-proprietary name “bezisterim” for NE3107
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April...
Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation
SAN DIEGO , March 26, 2024 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in BioVie Inc. (NASDAQ: BIVI) shares. Investors, who purchased shares of BioVie Inc. (NASDAQ: BIVI) prior to August 2021 and...
Source: https://incomestatements.info
Category: Stock Reports